Janssen has received positive opinions for two novel talquetamab and teclistamab bispecific antibodies for the trreatment of patients with Relapsed and Refractory Multiple Myeloma.
Talquetamab is a bispecific T-cell engaging antibody designed for the treatment of multiple myeloma. This antibody is engineered to bind to both CD3, which is present on T-cells, and GPRC5D, a protein that is highly expressed on multiple myeloma cells as well as on certain types of tissues.
Talquetamab is administered via subcutaneous injection and is under investigation in various clinical trials to assess its effectiveness and safety as a potential treatment for multiple myeloma.
On the other hand, Teclistamab represents a significant advancement in the realm of cancer treatment. As an off-the-shelf bispecific antibody, it offers a readily accessible therapeutic option for patients. Administered through subcutaneous injections, Teclistamab works by harnessing the power of two cellular targets, BCMA and CD3.
Multiple myeloma is indeed a complex and heterogeneous disease. Despite significant advancements in the treatment of multiple myeloma, it remains challenging to completely cure, and the disease's characteristics can vary widely among individuals.
Talquetamab, novel bispecific antibody is specifically designed to target GPRC5D, a protein that plays a significant role in the progression of multiple myeloma.
